Division of Cardiac Electrophysiology, Ochsner Medical Center, New Orleans, Louisiana.
Ochsner-West Bank, Gretna, Louisiana.
JAMA Cardiol. 2024 Jul 1;9(7):641-648. doi: 10.1001/jamacardio.2024.1091.
Atrial fibrillation and obesity are common, and both are increasing in prevalence. Obesity is associated with failure of cardioversion of atrial fibrillation using a standard single set of defibrillator pads, even at high output.
To compare the efficacy and safety of dual direct-current cardioversion (DCCV) using 2 sets of pads, with each pair simultaneously delivering 200 J, with traditional single 200-J DCCV using 1 set of pads in patients with obesity and atrial fibrillation.
DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, investigator-initiated, patient-blinded, randomized clinical trial spanning 3 years from August 2020 to 2023. As a multicenter trial, the setting included 3 sites in Louisiana. Eligibility criteria included body mass index (BMI) of 35 or higher (calculated as weight in kilograms divided by height in meters squared), age 18 years or older, and planned nonemergent electrical cardioversion for atrial fibrillation. Patients who met inclusion criteria were randomized 1:1. Exclusions occurred due to spontaneous cardioversion, instability, thrombus, or BMI below threshold.
Dual DCCV vs single DCCV.
Return to sinus rhythm, regardless of duration, immediately after the first cardioversion attempt of atrial fibrillation, adverse cardiovascular events, and chest discomfort after the procedure.
Of 2079 sequential patients undergoing cardioversion, 276 met inclusion criteria and were approached for participation. Of these, 210 participants were randomized 1:1. After exclusions, 200 patients (median [IQR] age, 67.6 [60.1-72.4] years; 127 male [63.5%]) completed the study. The mean (SD) BMI was 41.2 (6.5). Cardioversion was successful more often with dual DCCV compared with single DCCV (97 of 99 patients [98%] vs 87 of 101 patients [86%]; P = .002). Dual cardioversion predicted success (odds ratio, 6.7; 95% CI, 3.3-13.6; P = .01). Patients in the single cardioversion cohort whose first attempt failed underwent dual cardioversion with all subsequent attempts (up to 3 total), all of which were successful: 12 of 14 after second cardioversion and 2 of 14 after third cardioversion. There was no difference in the rating of postprocedure chest discomfort (median in both groups = 0 of 10; P = .40). There were no cardiovascular complications.
In patients with obesity (BMI ≥35) undergoing electrical cardioversion for atrial fibrillation, dual DCCV results in greater cardioversion success compared with single DCCV, without any increase in complications or patient discomfort.
ClinicalTrials.gov Identifier: NCT04539158.
心房颤动和肥胖症很常见,而且两者的发病率都在上升。肥胖症与使用标准的单个除颤垫进行心房颤动的复律失败有关,即使在高输出时也是如此。
比较使用 2 对电极片(每对同时输送 200J)的双相直流电复律(DCCV)与使用 1 对电极片(每对同时输送 200J)的传统单相 200J DCCV 在肥胖和心房颤动患者中的疗效和安全性。
设计、地点和参与者:这是一项前瞻性、研究者发起的、患者盲法、随机临床试验,历时 3 年,从 2020 年 8 月至 2023 年。作为一项多中心试验,该试验包括路易斯安那州的 3 个地点。入选标准包括体重指数(BMI)≥35(体重以千克为单位除以身高以米为单位的平方)、年龄 18 岁或以上、计划进行非紧急电复律治疗心房颤动。符合入选标准的患者以 1:1 的比例随机分组。由于自发复律、不稳定、血栓或 BMI 低于阈值而排除。
双相 DCCV 与单相 DCCV。
第一次复律尝试后立即恢复窦性节律,无论持续时间如何,心房颤动的不良心血管事件和程序后的胸痛。
在 2079 例连续接受复律的患者中,276 例符合纳入标准并被邀请参加。其中,210 名参与者以 1:1 的比例随机分组。排除后,200 名患者(中位数[IQR]年龄,67.6[60.1-72.4]岁;127 名男性[63.5%])完成了研究。平均(SD)BMI 为 41.2(6.5)。与单相 DCCV 相比,双相 DCCV 复律成功率更高(99 例患者中的 97 例[98%]与 101 例患者中的 87 例[86%];P=0.002)。双相复律预测成功率(优势比,6.7;95%CI,3.3-13.6;P=0.01)。单相复律组首次尝试失败的患者接受了双相复律,所有后续尝试(最多 3 次)均成功:第二次复律后 12 例,第三次复律后 2 例。两组术后胸痛评分无差异(中位数均为 0/10;P=0.40)。无心血管并发症。
在肥胖(BMI≥35)患者中,经电复律治疗心房颤动,与单相 DCCV 相比,双相 DCCV 可提高复律成功率,且无并发症或患者不适增加。
ClinicalTrials.gov 标识符:NCT04539158。